<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610777</url>
  </required_header>
  <id_info>
    <org_study_id>Pevonedistat-2001</org_study_id>
    <secondary_id>U1111-1169-6540</secondary_id>
    <secondary_id>2015-000221-37</secondary_id>
    <secondary_id>REec-2016-2145</secondary_id>
    <secondary_id>Pevonedistat-2001CTID</secondary_id>
    <nct_id>NCT02610777</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus&#xD;
      azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast&#xD;
      AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to&#xD;
      treat people with MDS or CMML, or low-blast AML as a combination treatment with azacitidine.&#xD;
      This study will look at the overall survival, event free survival and response to treatment&#xD;
      in people who take pevonedistat and azacitidine when compared to people who take single-agent&#xD;
      azacitidine.&#xD;
&#xD;
      The study will enroll 120 participants. Once enrolled, participants will be randomly assigned&#xD;
      (by chance, like flipping a coin) to one of the two treatment groups in 28-day treatment&#xD;
      cycles:&#xD;
&#xD;
        -  Pevonedistat 20 mg/m^2 and azacitidine 75 mg/m^2 combination&#xD;
&#xD;
        -  Single-agent azacitidine 75 mg/m^2&#xD;
&#xD;
      All participants will receive azacitidine via intravenous or subcutaneous route. Participants&#xD;
      randomized to the combination arm will also receive pevonedistat intravenous infusion.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall time to participate in this&#xD;
      study is approximately 44 months. Participants will attend the end-of-treatment visit 30 days&#xD;
      after the last dose of study drug or before the start of subsequent anti-neoplastic therapy&#xD;
      if that occurs sooner. Participants will enter event-free survival follow-up or response&#xD;
      follow-up (study visits every 3 months) if their disease has not transformed to AML (for&#xD;
      participants with HR MDS or CMML) or progressed (for participants with low-blast AML), and&#xD;
      they have not started subsequent therapy. Participants will also enter overall survival&#xD;
      follow-up (contacted every 3 months to document subsequent therapies and survival status).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">July 12, 2021</completion_date>
  <primary_completion_date type="Actual">September 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomization until death (up to 3 years and 5 months)</time_frame>
    <description>OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored at the date the participant was last known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>From date of randomization until transformation to AML, or death due to any cause (up to 5 years and 9 months)</time_frame>
    <description>EFS is defined as the time from the date of randomization to the date of the occurrence of an event. An event is defined as death or transformation to AML for HR MDS/CMML participants, whichever occurs first, or defined as death for low-blast AML participants. HR MDS/CMML participants without documented EFS event will be censored at the date of the last response assessment. HR MDS/CMML participants with no response assessment and no death will be censored at the date of randomization. Low-blast AML participants without documentation of death will be censored at the date the participant was last known to be alive. HR MDS/CMML participants who received alternative antineoplastic therapy before death or transformation to AML will be censored at the date of last adequate assessment prior to starting alternate antineoplastic therapy. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-month Survival Rate</measure>
    <time_frame>Month 6</time_frame>
    <description>Six-month survival rate (at 6 months) was defined as the Kaplan-Meier estimate of survival rate at 6 months. OS was defined as the time from the date of randomization to the date of death due to any cause. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Survival Rate</measure>
    <time_frame>Month 12</time_frame>
    <description>One-year survival rate (at 12 months) was defined as the Kaplan-Meier estimate of survival rate at 12 months. OS was defined as the time from the date of randomization to the date of death due to any cause. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to AML Transformation in HR MDS or CMML Participants</measure>
    <time_frame>From date of randomization until transformation to AML (up to 5 years and 9 months)</time_frame>
    <description>Time to AML transformation in HR MDS and CMML participants is defined as time from randomization to documented AML transformation. Participants who died before progression to AML will be censored. Transformation to AML is defined, according to World Health Organization (WHO) classification, as a participant having &gt;20% blasts in the blood or marrow and increase of blast count by 50%. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Remission (CR)</measure>
    <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
    <description>Disease responses for HR MDS or CMML is based on the modified International Working Group (IWG) response criteria for MDS and for low-blast AML on the revised IWG response criteria for AML. CR for HR MDS or CMML: less than or equal to (&lt;=) 5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to (&gt;=) 11 gram/deciliter (g/dL) hemoglobin (Hb), &gt;=100*10^9/liter (/L) platelets (plt), &gt;=1.0*10^9/L absolute neutrophil count (ANC) and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=1.0*10^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all of the criteria for CR except for residual neutropenia (&lt;1.0*10^9/L) or thrombocytopenia (TTP) (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR and Partial Remission (PR)</measure>
    <time_frame>From date of randomization until CR and PR (up to 5 years and 9 months)</time_frame>
    <description>Disease responses for HR MDS/CMML per modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML.CR for HR MDS/CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow ,&gt;=11 g/dL Hb;&gt;=100*10^9/L plt; &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood. PR for HR MDS/CMML:considered achieved if all CR criteria is met except for bone marrow blasts decreased by &gt;=50%over pretreatment but still &gt;5%. CR for low-blast AML: morphologic leukemia-free state, ANC of &gt;1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML:fulfill all criteria for CR except for residual neutropenia (&lt;100*10^9/L)/TTP(&lt;100*10^9/L). PR for low-blast AML:all hematological values for CR but with decrease of &gt;=50% in percentage of blasts to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response</measure>
    <time_frame>From date of randomization until CR, PR, or hematologic improvement (HI) (up to 5 years and 9 months)</time_frame>
    <description>Disease responses (HR MDS/CMML): modified IWG criteria for MDS; low-blast (LB) AML: revised IWG criteria for AML. Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+ CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines,&gt;=11g/dL Hb,&gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC,0% blasts in peripheral blood; PR:CR criteria met except BM blasts&gt;=50%less over pretreatment but still&gt;5%; HI:hb increase (inc)&gt;=1.5g/dL if baseline&lt;11g/dL;plt inc&gt;=30*10^9/L if baseline&gt;20*10^9/L/Inc. from &lt;20*10^9/L-&gt;20*10^9/L, ANC inc. by 100%;absolute inc. of&gt;0.5*10^9/L if baseline&lt;100*10^9/L. LB AML-CR:morphologic leukemia-freestate&gt;1.0*10^9ANC,&gt;=100*10^9/L plt, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L;PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR in Low-blast AML</measure>
    <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
    <description>Disease response for low-blast AML is based on the revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=1.0*10^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all of the criteria for CR except for residual neutropenia (&lt;1.0*10^9/L) or thrombocytopenia (TTP) (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR by Cycle 4</measure>
    <time_frame>From date of randomization until CR by Cycle 4 (cycle length is equal to [=] 28 days)</time_frame>
    <description>Disease responses for HR MDS or CMML were based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. CR for HR MDS or CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, and &gt;=11 g/dL Hb, &gt;=100*10^9/L plt, ANC &gt;=1.0*10^9/L and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L).Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR and PR by Cycle 4</measure>
    <time_frame>From date of randomization until CR and PR, by Cycle 4 (cycle length=28 days)</time_frame>
    <description>Disease responses for HR MDS/CMML per modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML.CR for HR MDS/CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, &gt;=11 g/dL Hb; &gt;=100*10^9/L plt; &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood.PR for HR MDS/CMML: considered achieved if all CR criteria is met except for bone marrow blasts decreased by&gt;=50% over pretreatment but still&gt;5%.CR for low-blast AML: morphologic leukemia-free state, ANC of&gt;1.0*10^9/L and plt of&gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: fulfill all criteria for CR except for residual neutropenia (&lt;100*10^9/L)/TTP (&lt;100*10^9/L). PR for low-blast AML: all hematological values for CR but with decrease of &gt;=50% in percentage of blasts to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response by Cycle 4</measure>
    <time_frame>From date of randomization until CR, PR or HI, by Cycle 4 (cycle length=28 days)</time_frame>
    <description>Disease responses (HR MDS/CMML): modified IWG criteria for MDS; low-blast (LB) AML: revised IWG criteria for AML. Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+ CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines,&gt;=11g/dL Hb,&gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC,0% blasts in peripheral blood; PR:CR criteria met except BM blasts&gt;=50%less over pretreatment but still&gt;5%; HI:hb increase (inc)&gt;=1.5g/dL if baseline&lt;11g/dL;plt inc&gt;=30*10^9/L if baseline&gt;20*10^9/L/Inc. from &lt;20*10^9/L-&gt;20*10^9/L, ANC inc. by 100%;absolute inc. of&gt;0.5*10^9/L if baseline&lt;100*10^9/L. LB AML-CR:morphologic leukemia-freestate&gt;1.0*10^9ANC,&gt;=100*10^9/L plt, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L;PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR in Low-blast AML by Cycle 4</measure>
    <time_frame>From the date of randomization until CR by Cycle 4 (cycle length=28 days)</time_frame>
    <description>Disease response for low-blast AML is based on revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and ptl of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
    <description>Duration of CR will be analyzed using standard survival analysis techniques based on Kaplan Meier estimates. Disease responses for HR MDS or CMML are based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. CR for HR MDS or CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, and &gt;=11 g/dL Hb, &gt;=100*10^9/L plt, &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR and PR</measure>
    <time_frame>From date of randomization until CR or PR (up to 5 years and 9 months)</time_frame>
    <description>Duration of CR and PR will be analyzed by standard survival analysis techniques based on Kaplan Meier estimates. Disease responses (HR MDS/CMML) are based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. For HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of all bone marrow cell lines, &gt;=11 g/dL Hb, &gt;=100*10^9/L plt,&gt;=1.0*10^9/L neutrophils, 0% blasts in peripheral blood;PR: all CR criteria met except bone marrow blasts &gt;=50% decrease over pretreatment but still &gt;5%; low-blast AML-CR: morphologic leukemia-free state, &gt;1.0*10^9/L ANC ,plt &gt;=100*10^9/L,transfusion independence, no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia &lt;1.0*10^9/L/TTP &lt;100*10^9/L;PR:all CR hematological values but with a decrease of &gt;=50% in blasts percentage to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response</measure>
    <time_frame>From date of randomization until CR, PR or HI (up to 5 years and 9 months)</time_frame>
    <description>Disease responses(HR MDS/CMML): modified IWG criteria for MDS;low-blast(LB)AML: revised IWG criteria for AML.Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR: &lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines, &gt;=11g/dL Hb,&gt;=100*10^9/L plt, &gt;=1.0*10^9/L ANC,0%blasts in peripheral blood; PR:CR criteria met except BM blasts &gt;=50%less over pretreatment but still&gt;5%; HI:hb increase(inc) &gt;=1.5g/dL if baseline&lt;11g/dL; plt inc&gt;=30*10^9/L if baseline &gt;20*10^9/L inc from&lt;20*10^9/L-&gt;20*10^9/L,ANC inc by100%; absolute inc of &gt;0.5*10^9/L if baseline &lt;100*10^9/L.LB AML-CR: morphologic leukemia-freestate &gt;1.0*10^9 ANC, &gt;=100*1 ^9/Lplt, transfusion independence, no residual evidence of extramedullary leukemia; CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L; PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR in Low-blast AML</measure>
    <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
    <description>Duration of CR was analyzed using standard survival analysis techniques based on Kaplan Meier estimates. Disease responses for low-blast AML is based on revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First CR or PR</measure>
    <time_frame>From date of randomization until CR or PR (up to 5 years and 9 months)</time_frame>
    <description>Time to first CR or PR: time from randomization to first documented CR or PR, whichever occurs first. Disease responses (HR MDS/CMML) based on modified IWG response criteria for MDS; low-blast AML on revised IWG response criteria for AML. HR MDS/CMML-CR: &lt;=5% myeloblasts with normal maturation of all bone marrow cell lines, &gt;=11 g/dL Hb, &gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts &gt;=50% decrease over pretreatment but still &gt;5%; For low-blast AML-CR: morphologic leukemia-free state, &gt;1.0*10^9/L ANC, plt &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia &lt;1.0*10^9/L/TTP &lt;100*10^9/L; PR: all CR hematological values but with a decrease of &gt;=50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Subsequent Therapy</measure>
    <time_frame>From date of randomization up to 5 year 9 months</time_frame>
    <description>Time to subsequent therapy is defined as time from randomization to the date of the first subsequent therapy. Subsequent therapy is defined as agent(s) with antileukemic/anti-MDS activity. Participants who discontinue study treatment to receive single-agent azacitidine off study will not be counted as receiving subsequent therapy. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence</measure>
    <time_frame>8 weeks before randomization through 30 days after last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>A participant was defined as RBC or platelet-transfusion independent if he/she receives no RBC or platelet transfusions for a period of at least 8 weeks before randomization through 30 days after the last dose of any study drug. Rate of transfusion independence is defined as number of participants who become transfusion independent divided by the number of participants who are transfusion dependent at Baseline. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML</measure>
    <time_frame>From date of randomization until transformation to AML or until initiation of subsequent therapy (up to 5 years and 9 months)</time_frame>
    <description>Inpatient hospital admission data will be collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurs first. Transformation to AML is defined, according to WHO Classification, as a participant having &gt;20% blasts in the blood or marrow and increase of blast count by 50%. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progressive Disease (PD), Relapse, or Death</measure>
    <time_frame>From date of randomization until PD, relapse or death (up to 5 years and 9 months)</time_frame>
    <description>Time from randomization until PD/transformation to AML/relapse/death due to any cause, whichever occurs first. Relapse after CR or PR in MDS/CMML: return to pretreatment bone marrow blast % or decrement of &gt;=50% from maximum remission levels in ANC or plt, reduction in Hb concentration by &gt;=1.5 g/dL or transfusion dependence. PD: at least 50% decrement from maximum remission in ANC or plt, or reduction in Hb by&gt;=2g/dL or transfusion dependence;participants with &lt;5% blasts: &gt;=50% increase (inc) in blasts to &gt;5%; 5%-10%: &gt;=50% inc to &gt;10%; 10%-20%: &gt;=50% inc to&gt;20%;20%-30%:&gt;=50% inc to &gt;30%. Relapse after CR in Low blast AML: reappearance of leukemic blasts in peripheral blood or &gt;=5% blasts in bone marrow not attributable to any cause (example, bone marrow regeneration after consolidation therapy). If there are no circulating blasts, bone marrow contains 5%-20% blasts, a repeat analysis is performed a week later. Data will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Clinical Laboratory Values</measure>
    <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline Values in Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>Number of participants with change from Baseline in ECOG performance status was measured on 6 point scale to assess participant's performance status, where: Grade 0(Normal activity. Fully active, able to carry on all pre-disease activities without restriction); Grade 1(Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); Grade 2(In bed &lt;50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours); Grade 3(In bed &gt;50% of the time. Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours); Grade 4(100% bedridden. Completely disabled, cannot carry on any self-care, totally confined to bed or chair); Grade 5(Dead). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Significant Change From Baseline in Electrocardiogram (ECG) Values</measure>
    <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline Values in Vital Signs</measure>
    <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
    <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myelomonocytic, Chronic</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine + Pevonedistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+ or - 10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine intravenous or subcutaneous formulation.</description>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_label>Azacitidine + Pevonedistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pevonedistat</intervention_name>
    <description>Pevonedistat intravenous infusion.</description>
    <arm_group_label>Azacitidine + Pevonedistat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants 18 years or older.&#xD;
&#xD;
          2. Morphologically confirmed diagnosis of MDS or nonproliferative CMML (that is, with&#xD;
             white blood cells [WBC] &lt;20,000 per microliter [/mcL]) or low blast AML based on 1 of&#xD;
             the following:&#xD;
&#xD;
             French American British (FAB) Classifications:&#xD;
&#xD;
               -  Refractory anemia with excess blasts (RAEB) - defined as having 5% to 20%&#xD;
                  myeloblasts in the bone marrow.&#xD;
&#xD;
               -  CMML with 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in&#xD;
                  the blood.&#xD;
&#xD;
             OR&#xD;
&#xD;
             WHO Classifications:&#xD;
&#xD;
               -  RAEB 1 - defined as having 5% to 9% myeloblasts in the bone marrow.&#xD;
&#xD;
               -  RAEB 2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to&#xD;
                  19% blasts in the blood.&#xD;
&#xD;
               -  CMML 2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to&#xD;
                  19% blasts in the blood.&#xD;
&#xD;
               -  CMML 1 (Although CMML 1 is defined as having &lt;10% myeloblasts in the bone marrow&#xD;
                  and/or &lt;5% blasts in the blood, these participants may enroll only if bone marrow&#xD;
                  blasts &gt;=5%.&#xD;
&#xD;
               -  WHO defined AML with 20% to 30% myeloblasts in the bone marrow and &lt;30%&#xD;
                  myeloblasts in peripheral blood who are deemed by the investigator to be&#xD;
                  appropriate for azacitidine based therapy.&#xD;
&#xD;
          3. For MDS and CMML participants, prognostic risk category, based on the Revised&#xD;
             International Prognostic Scoring System (IPSS R), of:&#xD;
&#xD;
               -  Very high (&gt;6 points),&#xD;
&#xD;
               -  High (&gt;4.5 to 6 points), or&#xD;
&#xD;
               -  Intermediate (&gt;3 to 4.5 points): a participant determined to be in the&#xD;
                  Intermediate Prognostic Risk Category is only allowable in the setting of &gt;=5%&#xD;
                  bone marrow myeloblasts.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          5. Clinical laboratory values within the following parameters (repeat within 3 days&#xD;
             before the first dose of study drug if laboratory values used for randomization were&#xD;
             obtained more than 3 days before the first dose of study drug):&#xD;
&#xD;
               -  Albumin &gt;2.7 g/dL.&#xD;
&#xD;
               -  Total bilirubin &lt;upper limit of normal (ULN) except in participants with&#xD;
                  Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct&#xD;
                  bilirubin &lt;=1.5*ULN of the direct bilirubin.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;2.5*ULN.&#xD;
&#xD;
               -  Creatinine clearance &gt;=50 milliliter per minutes (mL/min).&#xD;
&#xD;
               -  Hb &gt;8 g/dL. Participants may be transfused to achieve this value. Elevated&#xD;
                  indirect bilirubin due to post transfusion hemolysis is allowed.&#xD;
&#xD;
          6. For CMML participants: WBC count &lt;20,000/mcL before administration of the first dose&#xD;
             of study drug on Cycle 1 Day 1; participants must have been off hydroxyurea for at&#xD;
             least 1 week prior to WBC count assessment.&#xD;
&#xD;
          7. Ability to undergo the study required bone marrow sample collection procedures.&#xD;
&#xD;
          8. Suitable venous access for the study required blood sampling (that is, including&#xD;
             pharmacokinetic (PK) and biomarker sampling).&#xD;
&#xD;
          9. Female participants who:&#xD;
&#xD;
               -  Are postmenopausal for at least 1 year before the Screening visit , or&#xD;
&#xD;
               -  Are surgically sterile, or&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 1 highly effective&#xD;
                  method and 1 additional effective (barrier) method of contraception at the same&#xD;
                  time, from the time of signing the informed consent through 4 months after the&#xD;
                  last dose of study drug, or&#xD;
&#xD;
               -  Agree to practice true abstinence, when this is in line with the preferred and&#xD;
                  usual lifestyle of the participant. (Periodic abstinence [example, calendar,&#xD;
                  ovulation, symptothermal, postovulation methods] withdrawal, spermicides only,&#xD;
                  and lactational amenorrhea are not acceptable methods of contraception. Female&#xD;
                  and male condoms should not be used together).&#xD;
&#xD;
             Male participants, even if surgically sterilized (that is, status postvasectomy), who:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 4 months after the last dose of study drug, or&#xD;
&#xD;
               -  Agree to practice true abstinence, when this is in line with the preferred and&#xD;
                  usual lifestyle of the participant. (Periodic abstinence [example, calendar,&#xD;
                  ovulation, symptothermal, postovulation methods for the female partner]&#xD;
                  withdrawal, spermicides only, and lactational amenorrhea are not acceptable&#xD;
                  methods of contraception. Female and male condoms should not be used together).&#xD;
&#xD;
         10. Voluntary written consent must be given before performance of any study related&#xD;
             procedure not part of standard medical care, with the understanding that consent may&#xD;
             be withdrawn by the participant at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with decitabine or azacitidine or other hypomethylating agent.&#xD;
&#xD;
          2. Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow,&#xD;
             by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone&#xD;
             marrow, or by other accepted analysis.&#xD;
&#xD;
          3. Eligible for allogenic stem cell transplantation.&#xD;
&#xD;
          4. Participants with MDS, CMML, or low blast AML, whose only site of disease is&#xD;
             extramedullary, example, the skin.&#xD;
&#xD;
          5. Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of study procedures or could limit&#xD;
             participant expected survival to less than 6 months.&#xD;
&#xD;
          6. Treatment with any anti leukemic/anti MDS therapies (example, lenalidomide,&#xD;
             cytarabine, anthracyclines, purine analogs) or with any investigational products&#xD;
             within 14 days before the first dose of any study drug.&#xD;
&#xD;
          7. Known hypersensitivity to mannitol.&#xD;
&#xD;
          8. Active uncontrolled infection or severe infectious disease, such as severe pneumonia,&#xD;
             meningitis, or septicemia.&#xD;
&#xD;
          9. Major surgery within 14 days before first dose or a scheduled surgery during study&#xD;
             period; insertion of a venous access device (example, catheter, port) is not&#xD;
             considered major surgery.&#xD;
&#xD;
         10. Diagnosed or treated for another malignancy within 2 years before randomization or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type&#xD;
             are not excluded if they have undergone resection.&#xD;
&#xD;
         11. Life threatening illness unrelated to cancer.&#xD;
&#xD;
         12. Prothrombin time (PT) or prolongation of the activated thromboplastin time (aPTT) &gt;1.5&#xD;
             ULN or active uncontrolled coagulopathy or bleeding disorder.&#xD;
&#xD;
         13. Known human immunodeficiency virus (HIV) seropositive.&#xD;
&#xD;
         14. Known hepatitis B surface antigen seropositive, or known or suspected active hepatitis&#xD;
             C infection. Note: Participants who have isolated positive hepatitis B core antibody&#xD;
             (that is, in the setting of negative hepatitis B surface antigen and negative&#xD;
             hepatitis B surface antibody) must have an undetectable hepatitis B viral load.&#xD;
&#xD;
         15. Known hepatic cirrhosis or severe pre-existing hepatic impairment.&#xD;
&#xD;
         16. Known cardiopulmonary disease defined as unstable angina, clinically significant&#xD;
             arrhythmia, congestive heart failure (New York Heart Association [NYHA] Class III or&#xD;
             IV) and/or myocardial infarction within 6 months prior to first dose, or severe&#xD;
             pulmonary hypertension. As an example, well controlled atrial fibrillation would not&#xD;
             be an exclusion whereas uncontrolled atrial fibrillation would be an exclusion.&#xD;
&#xD;
         17. Treatment with strong cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days&#xD;
             before the first dose of study drug.&#xD;
&#xD;
         18. Systemic antineoplastic therapy or radiotherapy for other malignant conditions within&#xD;
             12 months before the first dose of any study drug, except for hydroxyurea.&#xD;
&#xD;
         19. Female participants who are lactating and breast feeding or have a positive serum&#xD;
             pregnancy test during the Screening period or a positive urine pregnancy test on Day 1&#xD;
             before first dose of study drug.&#xD;
&#xD;
         20. Female participants who intend to donate eggs (ova) during the course of this study or&#xD;
             4 months after receiving their last dose of study drug(s).&#xD;
&#xD;
         21. Male participants who intend to donate sperm during the course of this study or 4&#xD;
             months after receiving their last dose of study drug(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group Incorporated</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>6510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of South Texas</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Waco, TX</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi asbl</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Haematological Diseases - Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multi-Profile Hospital for Active Treatment Dr Georgi Stranski</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Akademisches Lehrkrankenhaus</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallaght Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>7010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid</name>
      <address>
        <city>Pozuelo De Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO I'Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet (ICO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga - Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Pevonedistat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02610777/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02610777/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 59 investigative sites in the United States, Canada, Belgium, Bulgaria, Czech Republic, Germany, Spain, France, Ireland, Israel, and Italy. Results are reported based on the primary completion date of 04 September 2019.</recruitment_details>
      <pre_assignment_details>Participants with higher-risk myelodysplastic syndrome (HR MDS) or chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML) were enrolled in this study to receive one of the two treatments: single-agent azacitidine or the combination of pevonedistat and azacitidine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azacitidine 75 mg/m^2</title>
          <description>Azacitidine 75 milligram per square meter (mg/m^2), infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
        <group group_id="P2">
          <title>Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2</title>
          <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing in Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing on Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (IIT) population was defined as all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Azacitidine 75 mg/m^2</title>
          <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
        <group group_id="B2">
          <title>Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2</title>
          <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="8.87"/>
                    <measurement group_id="B2" value="71.7" spread="9.63"/>
                    <measurement group_id="B3" value="70.6" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.12" spread="10.857"/>
                    <measurement group_id="B2" value="168.87" spread="7.510"/>
                    <measurement group_id="B3" value="169.00" spread="9.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.19" spread="18.471"/>
                    <measurement group_id="B2" value="75.95" spread="13.716"/>
                    <measurement group_id="B3" value="77.62" spread="16.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>square meter (m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.92" spread="0.265"/>
                    <measurement group_id="B2" value="1.88" spread="0.201"/>
                    <measurement group_id="B3" value="1.90" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored at the date the participant was last known to be alive.</description>
        <time_frame>From date of randomization until death (up to 3 years and 5 months)</time_frame>
        <population>The ITT population was defined as all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Azacitidine 75 mg/m^2</title>
            <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
          </group>
          <group group_id="O2">
            <title>Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2</title>
            <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored at the date the participant was last known to be alive.</description>
          <population>The ITT population was defined as all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="13.57" upper_limit="27.73"/>
                    <measurement group_id="O2" value="21.8" lower_limit="18.53" upper_limit="28.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio (HR) was based on an unstratified Cox proportional hazard regression model with treatment as a factor. P-value is from an unstratified log-rank test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.334</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.802</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.512</ci_lower_limit>
            <ci_upper_limit>1.256</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS)</title>
        <description>EFS is defined as the time from the date of randomization to the date of the occurrence of an event. An event is defined as death or transformation to AML for HR MDS/CMML participants, whichever occurs first, or defined as death for low-blast AML participants. HR MDS/CMML participants without documented EFS event will be censored at the date of the last response assessment. HR MDS/CMML participants with no response assessment and no death will be censored at the date of randomization. Low-blast AML participants without documentation of death will be censored at the date the participant was last known to be alive. HR MDS/CMML participants who received alternative antineoplastic therapy before death or transformation to AML will be censored at the date of last adequate assessment prior to starting alternate antineoplastic therapy. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until transformation to AML, or death due to any cause (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-month Survival Rate</title>
        <description>Six-month survival rate (at 6 months) was defined as the Kaplan-Meier estimate of survival rate at 6 months. OS was defined as the time from the date of randomization to the date of death due to any cause. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>Month 6</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-year Survival Rate</title>
        <description>One-year survival rate (at 12 months) was defined as the Kaplan-Meier estimate of survival rate at 12 months. OS was defined as the time from the date of randomization to the date of death due to any cause. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>Month 12</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to AML Transformation in HR MDS or CMML Participants</title>
        <description>Time to AML transformation in HR MDS and CMML participants is defined as time from randomization to documented AML transformation. Participants who died before progression to AML will be censored. Transformation to AML is defined, according to World Health Organization (WHO) classification, as a participant having &gt;20% blasts in the blood or marrow and increase of blast count by 50%. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until transformation to AML (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Remission (CR)</title>
        <description>Disease responses for HR MDS or CMML is based on the modified International Working Group (IWG) response criteria for MDS and for low-blast AML on the revised IWG response criteria for AML. CR for HR MDS or CMML: less than or equal to (&lt;=) 5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to (&gt;=) 11 gram/deciliter (g/dL) hemoglobin (Hb), &gt;=100*10^9/liter (/L) platelets (plt), &gt;=1.0*10^9/L absolute neutrophil count (ANC) and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=1.0*10^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all of the criteria for CR except for residual neutropenia (&lt;1.0*10^9/L) or thrombocytopenia (TTP) (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR and Partial Remission (PR)</title>
        <description>Disease responses for HR MDS/CMML per modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML.CR for HR MDS/CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow ,&gt;=11 g/dL Hb;&gt;=100*10^9/L plt; &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood. PR for HR MDS/CMML:considered achieved if all CR criteria is met except for bone marrow blasts decreased by &gt;=50%over pretreatment but still &gt;5%. CR for low-blast AML: morphologic leukemia-free state, ANC of &gt;1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML:fulfill all criteria for CR except for residual neutropenia (&lt;100*10^9/L)/TTP(&lt;100*10^9/L). PR for low-blast AML:all hematological values for CR but with decrease of &gt;=50% in percentage of blasts to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR and PR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Response</title>
        <description>Disease responses (HR MDS/CMML): modified IWG criteria for MDS; low-blast (LB) AML: revised IWG criteria for AML. Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+ CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines,&gt;=11g/dL Hb,&gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC,0% blasts in peripheral blood; PR:CR criteria met except BM blasts&gt;=50%less over pretreatment but still&gt;5%; HI:hb increase (inc)&gt;=1.5g/dL if baseline&lt;11g/dL;plt inc&gt;=30*10^9/L if baseline&gt;20*10^9/L/Inc. from &lt;20*10^9/L-&gt;20*10^9/L, ANC inc. by 100%;absolute inc. of&gt;0.5*10^9/L if baseline&lt;100*10^9/L. LB AML-CR:morphologic leukemia-freestate&gt;1.0*10^9ANC,&gt;=100*10^9/L plt, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L;PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR, PR, or hematologic improvement (HI) (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR in Low-blast AML</title>
        <description>Disease response for low-blast AML is based on the revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=1.0*10^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all of the criteria for CR except for residual neutropenia (&lt;1.0*10^9/L) or thrombocytopenia (TTP) (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR by Cycle 4</title>
        <description>Disease responses for HR MDS or CMML were based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. CR for HR MDS or CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, and &gt;=11 g/dL Hb, &gt;=100*10^9/L plt, ANC &gt;=1.0*10^9/L and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L).Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR by Cycle 4 (cycle length is equal to [=] 28 days)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR and PR by Cycle 4</title>
        <description>Disease responses for HR MDS/CMML per modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML.CR for HR MDS/CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, &gt;=11 g/dL Hb; &gt;=100*10^9/L plt; &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood.PR for HR MDS/CMML: considered achieved if all CR criteria is met except for bone marrow blasts decreased by&gt;=50% over pretreatment but still&gt;5%.CR for low-blast AML: morphologic leukemia-free state, ANC of&gt;1.0*10^9/L and plt of&gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: fulfill all criteria for CR except for residual neutropenia (&lt;100*10^9/L)/TTP (&lt;100*10^9/L). PR for low-blast AML: all hematological values for CR but with decrease of &gt;=50% in percentage of blasts to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR and PR, by Cycle 4 (cycle length=28 days)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Response by Cycle 4</title>
        <description>Disease responses (HR MDS/CMML): modified IWG criteria for MDS; low-blast (LB) AML: revised IWG criteria for AML. Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+ CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines,&gt;=11g/dL Hb,&gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC,0% blasts in peripheral blood; PR:CR criteria met except BM blasts&gt;=50%less over pretreatment but still&gt;5%; HI:hb increase (inc)&gt;=1.5g/dL if baseline&lt;11g/dL;plt inc&gt;=30*10^9/L if baseline&gt;20*10^9/L/Inc. from &lt;20*10^9/L-&gt;20*10^9/L, ANC inc. by 100%;absolute inc. of&gt;0.5*10^9/L if baseline&lt;100*10^9/L. LB AML-CR:morphologic leukemia-freestate&gt;1.0*10^9ANC,&gt;=100*10^9/L plt, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L;PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR, PR or HI, by Cycle 4 (cycle length=28 days)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR in Low-blast AML by Cycle 4</title>
        <description>Disease response for low-blast AML is based on revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and ptl of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From the date of randomization until CR by Cycle 4 (cycle length=28 days)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CR</title>
        <description>Duration of CR will be analyzed using standard survival analysis techniques based on Kaplan Meier estimates. Disease responses for HR MDS or CMML are based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. CR for HR MDS or CMML: &lt;=5% myeloblasts with normal maturation of all cell lines in bone marrow, and &gt;=11 g/dL Hb, &gt;=100*10^9/L plt, &gt;=1.0*10^9/L ANC and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CR and PR</title>
        <description>Duration of CR and PR will be analyzed by standard survival analysis techniques based on Kaplan Meier estimates. Disease responses (HR MDS/CMML) are based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. For HR MDS/CMML-CR:&lt;=5%myeloblasts with normal maturation of all bone marrow cell lines, &gt;=11 g/dL Hb, &gt;=100*10^9/L plt,&gt;=1.0*10^9/L neutrophils, 0% blasts in peripheral blood;PR: all CR criteria met except bone marrow blasts &gt;=50% decrease over pretreatment but still &gt;5%; low-blast AML-CR: morphologic leukemia-free state, &gt;1.0*10^9/L ANC ,plt &gt;=100*10^9/L,transfusion independence, no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia &lt;1.0*10^9/L/TTP &lt;100*10^9/L;PR:all CR hematological values but with a decrease of &gt;=50% in blasts percentage to 5%-25% in bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR or PR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Response</title>
        <description>Disease responses(HR MDS/CMML): modified IWG criteria for MDS;low-blast(LB)AML: revised IWG criteria for AML.Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+CR with incomplete blood count recovery(Cri)+PR.HR MDS/CMML-CR: &lt;=5%myeloblasts with normal maturation of bone marrow (BM) cell lines, &gt;=11g/dL Hb,&gt;=100*10^9/L plt, &gt;=1.0*10^9/L ANC,0%blasts in peripheral blood; PR:CR criteria met except BM blasts &gt;=50%less over pretreatment but still&gt;5%; HI:hb increase(inc) &gt;=1.5g/dL if baseline&lt;11g/dL; plt inc&gt;=30*10^9/L if baseline &gt;20*10^9/L inc from&lt;20*10^9/L-&gt;20*10^9/L,ANC inc by100%; absolute inc of &gt;0.5*10^9/L if baseline &lt;100*10^9/L.LB AML-CR: morphologic leukemia-freestate &gt;1.0*10^9 ANC, &gt;=100*1 ^9/Lplt, transfusion independence, no residual evidence of extramedullary leukemia; CRi:fulfill CR criteria except residual neutropenia&lt;1.0*10^9/L/TTP&lt;100*10^9/L; PR:all CR hematological values but&gt;=50%less in BM aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR, PR or HI (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CR in Low-blast AML</title>
        <description>Duration of CR was analyzed using standard survival analysis techniques based on Kaplan Meier estimates. Disease responses for low-blast AML is based on revised IWG response criteria for AML. CR for low-blast AML: morphologic leukemia-free state, ANC of more than 1.0*10^9/L and plt of &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery for low-blast AML: some participants fulfill all criteria for CR except for residual neutropenia (&lt;1.0*10^9/L)/TTP (&lt;100*10^9/L). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First CR or PR</title>
        <description>Time to first CR or PR: time from randomization to first documented CR or PR, whichever occurs first. Disease responses (HR MDS/CMML) based on modified IWG response criteria for MDS; low-blast AML on revised IWG response criteria for AML. HR MDS/CMML-CR: &lt;=5% myeloblasts with normal maturation of all bone marrow cell lines, &gt;=11 g/dL Hb, &gt;=100*10^9/L plt,&gt;=1.0*10^9/L ANC, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts &gt;=50% decrease over pretreatment but still &gt;5%; For low-blast AML-CR: morphologic leukemia-free state, &gt;1.0*10^9/L ANC, plt &gt;=100*10^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia &lt;1.0*10^9/L/TTP &lt;100*10^9/L; PR: all CR hematological values but with a decrease of &gt;=50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until CR or PR (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Subsequent Therapy</title>
        <description>Time to subsequent therapy is defined as time from randomization to the date of the first subsequent therapy. Subsequent therapy is defined as agent(s) with antileukemic/anti-MDS activity. Participants who discontinue study treatment to receive single-agent azacitidine off study will not be counted as receiving subsequent therapy. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 5 year 9 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence</title>
        <description>A participant was defined as RBC or platelet-transfusion independent if he/she receives no RBC or platelet transfusions for a period of at least 8 weeks before randomization through 30 days after the last dose of any study drug. Rate of transfusion independence is defined as number of participants who become transfusion independent divided by the number of participants who are transfusion dependent at Baseline. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>8 weeks before randomization through 30 days after last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML</title>
        <description>Inpatient hospital admission data will be collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurs first. Transformation to AML is defined, according to WHO Classification, as a participant having &gt;20% blasts in the blood or marrow and increase of blast count by 50%. Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until transformation to AML or until initiation of subsequent therapy (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progressive Disease (PD), Relapse, or Death</title>
        <description>Time from randomization until PD/transformation to AML/relapse/death due to any cause, whichever occurs first. Relapse after CR or PR in MDS/CMML: return to pretreatment bone marrow blast % or decrement of &gt;=50% from maximum remission levels in ANC or plt, reduction in Hb concentration by &gt;=1.5 g/dL or transfusion dependence. PD: at least 50% decrement from maximum remission in ANC or plt, or reduction in Hb by&gt;=2g/dL or transfusion dependence;participants with &lt;5% blasts: &gt;=50% increase (inc) in blasts to &gt;5%; 5%-10%: &gt;=50% inc to &gt;10%; 10%-20%: &gt;=50% inc to&gt;20%;20%-30%:&gt;=50% inc to &gt;30%. Relapse after CR in Low blast AML: reappearance of leukemic blasts in peripheral blood or &gt;=5% blasts in bone marrow not attributable to any cause (example, bone marrow regeneration after consolidation therapy). If there are no circulating blasts, bone marrow contains 5%-20% blasts, a repeat analysis is performed a week later. Data will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization until PD, relapse or death (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Clinical Laboratory Values</title>
        <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline Values in Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
        <description>Number of participants with change from Baseline in ECOG performance status was measured on 6 point scale to assess participant's performance status, where: Grade 0(Normal activity. Fully active, able to carry on all pre-disease activities without restriction); Grade 1(Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work); Grade 2(In bed &lt;50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours); Grade 3(In bed &gt;50% of the time. Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours); Grade 4(100% bedridden. Completely disabled, cannot carry on any self-care, totally confined to bed or chair); Grade 5(Dead). Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Significant Change From Baseline in Electrocardiogram (ECG) Values</title>
        <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline Values in Vital Signs</title>
        <description>Data for this outcome measure will be reported after study completion (which is planned for 2022).</description>
        <time_frame>From date of randomization up to 30 days after administration of the last dose of any study drug (up to 5 years and 9 months)</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs are adverse events (AEs) that started after the date of randomization up to 30 days after administration of the last dose of any study drug (up to 3 years and 5 months)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azacitidine 75 mg/m^2</title>
          <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
        <group group_id="E2">
          <title>Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2</title>
          <description>Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Days 1 to 5, and on Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Parophthalmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Ischaemic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oral viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome transformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="26" subjects_at_risk="62"/>
                <counts group_id="E2" events="35" subjects_affected="18" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="18" subjects_at_risk="62"/>
                <counts group_id="E2" events="62" subjects_affected="20" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E2" events="35" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="62"/>
                <counts group_id="E2" events="38" subjects_affected="21" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="39" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E2" events="34" subjects_affected="20" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="62"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="22" subjects_at_risk="62"/>
                <counts group_id="E2" events="36" subjects_affected="21" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="62"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" events="27" subjects_affected="17" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="22" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="16" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="62"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

